Draft Guidance for Industry; Availability, etc.:

Text

---

Federal Register: October 14, 2010 (Volume 75, Number 198)

Notices

Page 63188-63189

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr14oc10-81

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket No. FDA-2010-D-0500

Draft Guidance for Industry: Early Clinical Trials With Live

Biotherapeutic Products: Chemistry, Manufacturing, and Control

Information; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

Page 63189

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft document entitled ``Guidance for Industry:

Early Clinical Trials with Live Biotherapeutic Products: Chemistry,

Manufacturing, and Control Information'' dated September 2010. The draft guidance provides investigational new drug application (IND) sponsors with recommendations on the submission of INDs for early clinical trials with live biotherapeutic products (LBPs).

DATES: Although you can comment on any guidance at any time (21 CFR 10.115(g)(5)), to ensure that the agency considers your comments on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by December 13, 2010.

ADDRESSES: Submit written requests for single copies of the draft guidance to the Office of Communication, Outreach and Development (HFM- 40), Center for Biologics Evaluation and Research (CBER), Food and Drug

Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852- 1448. Send one self-addressed adhesive label to assist the office in processing your requests. The draft guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 301-827-1800. See the

SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.

Submit electronic comments on the draft guidance to http:// www.regulations.gov. Submit written comments to the Division of Dockets

Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Benjamin A. Chacko, Center for

Biologics Evaluation and Research (HFM-17), Food and Drug

Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852- 1448, 301-827-6210.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft document entitled

``Guidance for Industry: Early Clinical Trials with Live Biotherapeutic

Products: Chemistry, Manufacturing, and Control Information'' dated

September 2010. The draft guidance provides IND sponsors with recommendations on the submission of INDs for early clinical trials with LBPs.

Regulations in part 312 (21 CFR part 312) require sponsors who wish to study LBPs in humans to submit an IND to FDA, unless the sponsor falls into one of the exemptions for clinical investigations found under Sec. 312.2(b). The general principles underlying the IND submission and the general requirements for an IND's content and format are contained in Sec. Sec. 312.22 and 312.23, respectively. This draft guidance focuses on the chemistry, manufacturing, and control information that should be provided in an IND in order to meet the requirements under Sec. 312.23 for early clinical trials evaluating

LBPs. This draft guidance is applicable to all INDs of LBPs, whether clinical trials are conducted commercially, in an academic setting, or otherwise (Sec. 312.2).

The draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent FDA's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirement of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

This draft guidance refers to previously approved collections of information found in FDA regulations. The collections of information in 21 CFR part 312 have been approved under the Office of Management and

Budget (OMB) control number 0910-0014.

III. Comments

The draft guidance is being distributed for comment purposes only and is not intended for implementation at this time. Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

IV. Electronic Access

Persons with access to the Internet may obtain the draft guidance at either http://www.fda.gov/BiologicsBloodVaccines/

GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http:/

/www.regulations.gov.

Dated: October 7, 2010.

Leslie Kux,

Acting Assistant Commissioner for Policy.

FR Doc. 2010-25850 Filed 10-13-10; 8:45 am

BILLING CODE 4160-01-P

---